Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Importation Would Lead To Two Drug Classes – FDA Chief Counsel Troy

Executive Summary

A legalized drug importation system would likely lead to the emergence of two classes of drugs, FDA Chief Counsel Dan Troy predicted

You may also be interested in...

Wholesalers Crucial To Safe Rx Importation Scheme, HDMA Tells Task Force

Wholesalers are fundamental to the integrity of any legalized drug importation system, the Healthcare Distribution Management Association told the HHS drug importation task force

PhRMA Braces For Import Fight; Trade Treaties May Help, Sen. Breaux Says

Every U.S. trade agreement should be examined for its potential impact on prescription drug pricing, Sen. John Breaux (D-La.) said during the Pharmaceutical Research & Manufacturers of America's annual meeting in Palm Beach, Fla. April 3

Rx Import Task Force Seeks Information On FDA-Approved Drugs Sold Abroad

FDA is working to determine the number of drugs sold abroad that are manufactured and labeled according to U.S. standards, former FDA Commissioner McClellan told a meeting of the HHS importation task force




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts